BCMA CAR-T: From Multiple Myeloma to Light-Chain Amyloidosis
Current Oncology · 2025
DOI: 10.3390/curroncol32080418 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, 2025. Verfasst von Ellen Lewis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Arthur Child Comprehensive Cancer Centre, Calgary, AB T2N 4N2, Canada. Hauptthemen laut MEDLINE: Multiple Myeloma, B-Cell Maturation Antigen, Immunoglobulin Light-chain Amyloidosis, Immunotherapy, Adoptive. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Light-chain (AL) amyloidosis is a rare clonal plasma cell disorder that, if left untreated, carries a high risk of organ damage and mortality. Due to the rarity of the disease and the vulnerability of affected organ systems, treatment requires significant caution and nuance. As a plasma cell dyscrasia, AL amyloidosis treatment regimens are often adapted from those used for related disorders, particularly multiple myeloma. Despite substantial progress in research and drug development, optimal treatment strategies for relapsed/refractory (RR) AL amyloidosis remain unclear, and no FDA-approved therapies currently exist for this setting. B-cell maturation antigen (BCMA) has emerged as a promising immunotherapy target, with associated drug classes including antibody–drug conjugates, bispecific antibodies, and CAR-T cell therapies. These therapies have been extensively studied in relapsed/refractory multiple myeloma (RRMM) and are now being explored in the context of RR AL amyloidosis. This review summarizes the current literature on the efficacy and tolerability of BCMA-directed therapies in AL amyloidosis, with a particular emphasis on CAR-T cell therapy and offers comparisons to outcomes observed in RRMM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Arthur Child Comprehensive Cancer Centre, Calgary, AB T2N 4N2, Canada.
- Division of Hematology, Department of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
- Arnie Charbonneau Cancer Research Institute, Calgary, AB T2N 4N2, Canada.
ORCID-Profile: Victor Hugo Jimenez-Zepeda
Zitieren
APA
Lewis, E., & Jimenez-Zepeda, V. H. (2025). BCMA CAR-T: From Multiple Myeloma to Light-Chain Amyloidosis. Current Oncology. https://doi.org/10.3390/curroncol32080418
Vancouver
Lewis E, Jimenez-Zepeda VH. BCMA CAR-T: From Multiple Myeloma to Light-Chain Amyloidosis. Current Oncology. 2025. doi:10.3390/curroncol32080418
BibTeX
@article{Lewis2025,
author = {Lewis, Ellen and Jimenez-Zepeda, Victor Hugo},
title = {BCMA CAR-T: From Multiple Myeloma to Light-Chain Amyloidosis},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32080418}
}
EUVIMED